Daiichi Sankyo company information, Employees & Contact Information

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO Yahoo Finance

DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial Business Wire

Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants Wiley

Process Development of a PI3Kδ Inhibitor: A Novel and Practical [1,2]-Boc Migration on Purine Rings ACS Publications

Daiichi Sankyo Establishes Third Research Institute in San Diego Yahoo Finance

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPIO Business Wire

Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 E PharmiWeb.com

Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged ≥12 years medRxiv

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC Yahoo Finance

Daiichi Sankyo and MassBio Team Up to Identify Cutting-Edge Science and Technology Massachusetts Biotechnology Council

Daiichi Sankyo Joins LabCentral Community as Platinum Sponsor PR Newswire

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer Business Wire

Process Development of Purpurin 18: Paving the Way for Kilogram-Scale Manufacturing of Chlorophyll a Derivatives ACS Publications

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer Yahoo Finance

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors Yahoo Finance

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer citybiz

Process Development of Purpurin 18: Paving the Way for Kilogram-Scale Manufacturing of Chlorophyll a Derivatives ACS Publications

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC OncLive

Company Profile: Daiichi Sankyo pharmaphorum

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH citybiz

Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs Business Wire

Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non-Hodgkin lymphoma Wiley

Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC Urology Times

Daiichi Sankyo Announces New CEO Pharmaceutical Executive

Bayesian sparse regression for exposure–response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma Wiley

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C Yahoo Finance

QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML Yahoo Finance

Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 Business Wire

Valemetostat Tosilate Approved in Japan for R/R PTCL OncLive

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer Yahoo Finance

Daiichi Sankyo, Inc. Publishes Second Edition of Pain Trends Report PR Newswire

FDA Approves Intravenous Iron Replacement Therapy for Heart Failure Patients Diagnostic and Interventional Cardiology

ENDEAVOUR Lung Cancer Program Forms International Teams to Initiate Four Collaborative Projects Focused on Advancing Patient Care Business Wire

The Innovation, Care, and Compassion of Daiichi Sankyo – Part 2 European Medical Journal

Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio Business Wire

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer Business Wire

Daiichi Sankyo, Inc. Launches CommitmentsinPainCare.com PR Newswire

30% Survival Rate Target: Merck's New Phase 3 Trial Aims to Transform HR+ Breast Cancer Treatment Stock Titan

Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase Business Wire

Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to "Get Iron Informed" PR Newswire

Daiichi Sankyo, Inc. Adds to Its Dynamic Team, Welcoming Leigh Ann Errico as the New Vice President of Human Resources for the U.S. Commercial Group PR Newswire

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of MultiVu

ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer The AI Journal

Daiichi Sankyo - Benicar Manufacturer, History, Products Drugwatch.com

Approved in the U.S. for the Treatment of Patients with Previously Treated HER2 Positive Advanced Gastric Cancer Business Wire

ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye GlobeNewswire

VANFLYTA® is Now Approved in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML PR Newswire Canada

American Regent Announces the Launch and Availability of Selenious Acid Injection, USP­ PR Newswire

Daiichi Sankyo and AstraZeneca to co-launch MOVANTIK European Pharmaceutical Review

Merger between Daiichi Sankyo subsidiary Ranbaxy and Sun Pharma completed European Pharmaceutical Review

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk European Pharmaceutical Review

ENHERTU ® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy Via TT

Daiichi Sankyo’s Once-Daily Lixiana® (edoxaban) receives positive CHMP opinion Hospital Pharmacy Europe

Daiichi Sankyo to Acquire Ambit Biosciences PR Newswire UK

ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye NTB Kommunikasjon